GLP-1 receptor agonists may help obese patients lose weight faster before hernia surgery compared to lifestyle changes alone, without increasing surgical complications or hernia recurrence.
Earlier surgery dateGLP-1 receptor agonists got patients to hernia surgery faster than both lifestyle modifications and bariatric surgery when weight loss was the barrier, without increasing post-operative complications.
What the researchers found
Three retrospective studies showed that neoadjuvant GLP-1 receptor agonists in obese patients awaiting abdominal wall hernia repair:
- Achieved significantly greater or equivalent weight loss and BMI reductions compared to conventional lifestyle modifications alone
- Did not match pre-operative bariatric surgery in total weight loss and BMI reduction
- Were associated with earlier surgery dates when weight loss was the barrier to proceeding, outperforming both lifestyle modifications and bariatric surgery timelines
- Were not associated with increased post-operative complications or hernia recurrence rates
The review concludes there may be a promising role for GLP-1 drugs as a neoadjuvant bridge to surgery in obese hernia patients.
Why it matters
Obesity is both a cause of hernias and a major risk factor for surgical complications. Many surgeons delay hernia repair until patients lose weight, but conventional weight loss is slow and often unsuccessful. GLP-1 receptor agonists offer a pharmacological solution that could get patients to surgery faster and in better condition. This review provides the first evidence synthesis for this increasingly common clinical scenario, supporting a practical new use for these popular peptide drugs.
How the study worked
The authors conducted a narrative review with a computer-assisted search of Medline, PubMed, and EMBASE databases to identify studies reporting on GLP-1 receptor agonist use for pre-operative weight loss before abdominal wall hernia surgery. Three retrospective studies met inclusion criteria and were synthesized qualitatively.
What this study cannot tell us
Only three retrospective studies were available, severely limiting the evidence base. There was significant heterogeneity among the included studies. No randomized controlled trials exist for this indication. Long-term outcomes (beyond immediate post-operative period) are unknown. The effects of GLP-1 drugs on wound healing, tissue quality, and muscle mass — all relevant to hernia repair — were not specifically addressed. Anesthesia-related concerns about GLP-1 drugs (delayed gastric emptying and aspiration risk) were not discussed in the abstract.
How to read the evidence
This is a narrative review of only three retrospective studies, representing a very early and limited evidence base. While the findings are consistently positive, the absence of randomized controlled trials, the small number of studies, and their retrospective design place this at a low evidence level. The review is best interpreted as hypothesis-generating.
When this study was published
Published in 2026, this is a brand-new review addressing a very current clinical question as GLP-1 receptor agonist use expands rapidly. The surgical community is actively debating how to integrate these drugs into pre-operative protocols.
The bigger picture
GLP-1 receptor agonists are expanding beyond diabetes and obesity treatment into surgical optimization. The concept of 'prehabilitation' — preparing patients medically before surgery — is growing across surgical specialties. This review represents an early example of how peptide-based weight loss drugs could transform surgical planning by reducing the delay between diagnosis and operation, particularly for conditions where obesity complicates both the surgery and recovery.
Questions still open
- What is the optimal duration of GLP-1 therapy before hernia surgery to maximize surgical benefit while minimizing delay?
- Do GLP-1 receptor agonists affect wound healing or tissue quality in ways that could impact hernia repair outcomes?
- Should GLP-1 drugs be stopped before surgery given concerns about delayed gastric emptying and anesthesia risk?
Common questions
Why would a surgeon want me to lose weight before hernia surgery?
Is it safe to use GLP-1 drugs right before surgery?
Read the original research
Neoadjuvant Glucagon-Like Peptide-1 Receptor Agonists in Abdominal Wall Hernia Surgery: A Narrative Review.
World journal of surgery
Citation
Prabhakaran, Swetha; Wells, Oliver; Tsui, Lap Wah; Kong, Joseph Cherng Huei. (2026). Neoadjuvant Glucagon-Like Peptide-1 Receptor Agonists in Abdominal Wall Hernia Surgery: A Narrative Review.. World journal of surgery. https://doi.org/10.1002/wjs.70260